Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20595959 | 0.82 | EGFR (0.39) | MEN1KMT2AMAPTCYP2C19CYP2C9 | |
| SCHEMBL20596534 | 0.76 | LMNA (0.39) | MEN1KMT2AMAPK1MAPTCYP2C19 | |
| SCHEMBL20596647 | 0.75 | MEN1 (0.36) | MEN1KMT2AMAPK1MAPTTP53 | |
| SCHEMBL20595626 | 0.74 | ALDH1A1 (0.44) | MEN1KMT2AMAPK1MAPTCYP2C19 | |
| SCHEMBL23419709 | 0.74 | KDM4E (0.42) | MEN1KMT2AMAPK1MAPTCYP2C19 | |
| SCHEMBL30145258 | 0.73 | MARS2 (0.51) | CYP2C9SMN1; SMN2LMNAHTT | |
| SCHEMBL20595855 | 0.73 | MARS2 (0.51) | CYP2C9SMN1; SMN2LMNAHTT | |
| SCHEMBL20596066 | 0.73 | POLB (0.45) | MEN1KMT2AMAPK1MAPTCYP2C19 | |
| SCHEMBL20596490 | 0.71 | MARS2 (0.42) | MEN1KMT2AMAPK1MAPTTP53 | |
| SCHEMBL20595835 | 0.69 | MEN1 (0.38) | MEN1KMT2AMAPK1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584744-B2 | Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them | UNIVERSITY OF WASHINGTON (US) | 2023-02-21 | — | — | US | disclosed |
| US-20210155617-A1 | INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM | UNIVERSITY OF WASHINGTON | 2021-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584744-B2 | Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them | AARS1, EMG1, GARS1 | MEN1 1598/4885KMT2A 1475/4885MAPK1 4114/4885 |
| US-20210155617-A1 | INHIBITORS OF TYPE l METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM | AARS1, GARS1, MTR | MEN1 2393/4885KMT2A 1280/4885MAPK1 4685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.